| Patients (%) | REBLOZYL | Epoetin Alfa |
|---|---|---|
| ITT POPULATION* | 60% (n=110/182) |
35% (n=63/181) |
| BASELINE TRANSFUSION BURDEN | ||
| <4 | 67% (n=79/118) |
43% (n=48/111) |
| ≥4 | 48% (n=31/64) |
21% (n=15/70) |
| BASELINE sEPO | ||
| ≤200 U/L | 66% (n=96/145) |
41% (n=59/144) |
| >200 to <500 U/L | 38% (n=14/37) |
11% (n=4/37) |
| SF3B1 MUTATION STATUS | ||
| Mutated | 70% (n=80/114) |
33% (n=33/101) |
| Non-mutated | 45% (n=29/65) |
36% (n=26/72) |
| RS STATUS | ||
| RS+ | 65% (n=87/133) |
29% (n=38/130) |
| RS- | 47% (n=23/49) |
50% (n=25/50) |
WHY TREAT WITH REBLOZYL:
SUBGROUP DATA
COMMANDS subgroup data
REBLOZYL was studied head-to-head against EA in adult patients with anemia due to LR-MDS who were ESA-naive and required transfusions. Primary endpoint: 58.5% of patients taking REBLOZYL achieved the primary composite endpoint of ≥12 week red blood cell TI and Hgb increase ≥1.5 g/dL (n=86/147; 95% CI: 50.1, 66.6) vs 31.2% of patients taking EA (n=48/154; 95% Cl: 24.0, 39.1).1
FROM THE PRIMARY ANALYSIS OF THE COMMANDS TRIAL REBLOZYL results across key subgroups2
RESPONSE RATES OF THE ITT POPULATION AND SUBGROUPS OF RBC-TI LASTING ≥12 WKS AND MEAN Hgb OF ≥1.5 g/dL DURING WKS 1-242
Select graphic view or text view to explore data
*P<0.0001.2
Data cutoff date: September 2023.2
FROM THE FULL ANALYSIS 48-WEEK FOLLOW-UP3† COMMANDS had 99 RS- patients, the most of any Phase 3 LR-MDS study3
DURATION OF RBC-TI FOR ≥12 WKS AMONG RS- PATIENTS
Select KM curve or graphic view to explore data
Duration for REBLOZYL arm was not reached (NR) because >50% of patients were still transfusion independent at time of analysis1
Analysis limitations4:
- Subgroup analyses were performed for the primary and key secondary efficacy endpoints. Formal hypothesis testing was not performed in the subgroup analysis
- These preplanned subgroup analyses should not be interpreted to determine treatment differences between arms in these subgroups due to limited sample size, lack of statistical hypothesis testing, and increased probability of a false-positive finding
†Exploratory endpoint.3
Data cutoff date: September 2023.3
CI=confidence interval; EA=epoetin alfa; EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; Hgb=hemoglobin; ITT=intention to treat; KM=Kaplan-Meier; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; RBC=red blood cell; RBC-TI=red blood cell transfusion independent; RS=ring sideroblast; sEPO=serum erythropoietin; TB=transfusion burden; TI=transfusion independence.
Hear what one clinical expert has to say about key patient groups
References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2026. 2. Della Porta MG, Garcia-Manero G, Santini V, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024;11(9)(suppl):e646-e658. doi:10.1016/52352-3026(24)00203-5 3. Garcia-Manero G, Platzbecker U, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes: full analysis of the COMMANDS trial. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition. December 9-12, 2023. San Diego, CA. Abstract 193. 4. Data on file. BMS-REF-ACE-536-0009. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
